Drug Profile

Estradiol acetate - AbbVie

Alternative Names: ESTRACE; Estradiol acetate intravaginal ring; Estradiol acetate IVR; Femring; Menoring

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Warner Chilcott
Developer Allergan; Warner Chilcott
Class Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
Mechanism of Action Estrogen receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Atrophic vaginitis; Menopausal syndrome; Vasomotor symptoms

Most Recent Events

08 May 2020 Allergan has been acquired and merged into AbbVie
29 Dec 2017 First Generic equivalent available in USA for Atrophic vaginitis
01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com